OmniAb Inc. (OABI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OmniAb Inc. (OABI) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.76 Million) by net assets ($277.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check OmniAb Inc. (OABI) strategic asset index to assess the company's strategic physical and investment asset allocation.
OmniAb Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how OmniAb Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. See OABI total equity for net asset value and shareholders' equity analysis.
OmniAb Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OmniAb Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Saha-Union Public Company Limited
BK:SUC
|
0.010x |
|
Huuuge Inc.
WAR:HUG
|
0.114x |
|
Petronor E&P Ltd
OL:PNOR
|
-0.047x |
|
Healthco Healthcare and Wellness REIT
AU:HCW
|
0.016x |
|
Mastersystem Infotama Tbk.
JK:MSTI
|
-0.053x |
|
Millenium Hotels Real Estate I SOCIMI S.A.
MC:YMHRE
|
-0.005x |
|
Fujian Sanmu Group Co Ltd
SHE:000632
|
-0.347x |
|
First Insurance Co Ltd
TW:2852
|
0.033x |
Annual Cash Flow Conversion Efficiency for OmniAb Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of OmniAb Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see OABI market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.62 Million | $-39.66 Million | -0.138x | -1948.44% |
| 2023-12-31 | $314.58 Million | $2.35 Million | 0.007x | +171.00% |
| 2022-12-31 | $341.37 Million | $-3.59 Million | -0.011x | +56.59% |
| 2021-12-31 | $234.31 Million | $-5.67 Million | -0.024x | -257.55% |
| 2020-12-31 | $235.54 Million | $3.62 Million | 0.015x | +164.53% |
| 2019-12-31 | $218.19 Million | $-5.20 Million | -0.024x | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more